Standard Haematology Practice

Haematology in general practice.

Biosimilar agents in oncology/haematology: from approval to practice

The regulation of biosimilars is a process that is still developing. In Europe, guidance regarding the approval and use of biosimilars has evolved with the products under consideration. It is now more than 3 years since the first biosimilar agents in oncology support, erythropoiesis-stimulating agents, were approved in the EU. More recently, biosimilar granulocyte colony-stimulating factors hav...

Angioplasty standard of practice.

PERCUTANEOUS transluminal angioplasty (PTA) and other methods of percutaneous revascularization have become established as effective therapy for selected patients with peripheral and renovascular occlusive diseases. Extensive literature now documents the safety and efficacy of PTA in the management of atherosclerotic and other vascular diseases (1–14). As with any invasive therapy, the potentia...

Haematology in Tropical Areas: Clinics in Haematology

CLINICS in Haematology were introduced some 10 years ago to provide in depth reviews of different aspects of the discipline and have become an accepted and highly respected part of haematology literature. To mark the 10th anniversary there has been a break from tradition and rather than dealing with a specialised topic, the present issue is devoted to Haematology in Tropical Areas. That the spe...

Sports haematology.

While the crucial role of haemoglobin in aerobic exercise has been well accepted, there is still a great deal of controversy about the optimal haematological parameters in the athletic population. The initial part of this review will examine the question of anaemia in athletes. The most common finding in athletes is a dilutional pseudoanaemia that is caused by a plasma volume expansion, rather ...